Metraipolis › archive › dc_93cf03b765d2

CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non-adverse-risk AML: the NCRI AML18 trial — Europe PMC PMID:41237344

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41237344
DOI
10.1182/blood.2025031006
License (as archived)
solo-consultazione
Archived
2026-10-08T06:02:51.128Z
SHA-256 of the archived text
cc51da4448dbbae0631ba1fb342a6e1a71c144929326886cb3214580b3e45656
Stable URL of this page
https://metraipolis.com/documento/dc_93cf03b765d2

How to cite

CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non-adverse-risk AML: the NCRI AML18 trial — Europe PMC PMID:41237344 — Europe PMC (en), https://europepmc.org/article/MED/41237344 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_93cf03b765d2 (Metraipolis archive dc_93cf03b765d2, sha256 cc51da4448dbbae0631ba1fb342a6e1a71c144929326886cb3214580b3e45656)
BibTeX
@misc{dc93cf03b765d2,
  title = {CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non-adverse-risk AML: the NCRI AML18 trial — Europe PMC PMID:41237344},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41237344},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_93cf03b765d2; sha256 cc51da4448dbbae0631ba1fb342a6e1a71c144929326886cb3214580b3e45656},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41237344. Agents can read the archived copy with the MCP tool read_document.